1. Report Introduction 2. B-Cell Chronic Lymphocytic Leukemia Overview 3. Pipeline Therapeutics • An Overview of Pipeline Products for B-Cell Chronic Lymphocytic Leukemia 4. Comparative Analysis 5. Products in Clinical Stage 5.1 Drug Name : Company Name • Product Description • Research and Development • Product Development Activities 6. Products in Pre-Clinical and Discovery Stage 6.1 Drug Name : Company Name • Product Description • Research and Development • Product Development Activities 7. Therapeutic Assessment • Assessment by Route of Administration • Assessment by Stage and Route of Administration • Assessment by Molecule Type • Assessment by Stage and Molecule Type 8. Inactive Products 8.1 Drug Name : Company Name • Product Description • Research and Development • Product Development Activities Appendix Report Methodology Consulting Services Disclaimer About DelveInsight

Table 1: Total Products for B-Cell Chronic Lymphocytic Leukemia Table 2: Products in Clinical Stage Table 3: Products in Non-clinical Stage Table 4: Assessment by Route of Administration Table 5: Assessment by Stage and Route of Administration Table 6: Assessment by Molecule Type Table 7: Assessment by Stage and Molecule Type Table 8: Inactive Products Figure 1: Total Products for B-Cell Chronic Lymphocytic Leukemia Figure 2: Products in Clinical Stage Figure 3: Products in Non-clinical Stage Figure 4: Assessment by Route of Administration Figure 5: Assessment by Stage and Route of Administration Figure 6: Assessment by Molecule Type Figure 7: Assessment by Stage and Molecule Type Figure 8: Inactive Products

AbbVie Acerta Pharma BVTG Therapeutics Inc. Verastem Inc. GlaxoSmithKline Gilead Pharmacyclics Berlex Laboratories Cephalon GenentechAB Amgen Inc. Celgene Corporation Dynavax Technologies Corporation Eisai Co. Ltd. & list continues...